Objective: Depression is associated with increased mortality in community samples. The use of antidepressant medication may also increase mortality, however, it is still unclear whether taking antidepressants before or after a diagnosis of dementia influences survival.
Introduction
There is increasing recognition that psychiatric comorbidities are a common and distressing feature among people with Alzheimer's disease (AD), 1 of which depression is one of the most prevalent and troubling. 2 Previous meta-analyses have concluded that depression is associated with increased risk of a person developing AD, potentially due to inflammatory processes, stress or reduced cognitive reserve. 3 Furthermore, the prevalence of depression among people with AD may be as high as 80% 4, 5 , and probably associated with higher mortality 6 , greater medical comorbidity and poorer quality of life for the individual and careers 7 .
Antidepressant medications are a commonly used treatment for depression in the general population 8 and are also used in people with AD, 9 although there is uncertainty as to the benefits in people affected by dementia and/or AD. Some trials support a beneficial effect [10] [11] [12] but more recent studies report that antidepressants are not effective 13, 14 as indicated by a Cochrane review. 15 In addition, there is a contentious debate about the potential association between antidepressant medication and higher mortality among people with AD. In the general population, there have been mixed results for this association, including lower mortality 16 , no association 17 and higher mortality. 18 However, information on people with AD remains sparse. One previous study among people with dementia, found that antidepressant medication was associated with a significantly higher mortality risk of 36%, 19 but another study found 18% lower mortality in people taking antidepressant medications for 3 years before an AD diagnosis. 20 Given the high comorbidity of depression among people with AD, the common use of antidepressants, but paucity of studies on the relationship with mortality in this population, we aimed to investigate the association between the use of antidepressants and mortality in a large cohort of people with diagnosed AD.
Methods

Data Source and Setting
We obtained the data for this study using the South London and Maudsley NHS Foundation 25 .
Variables
To distinguish longstanding antidepressant use from use associated with the diagnosis of dementia we defined two exposure groups. Patients were classified as prescribed antidepressants prior to dementia diagnosis if any antidepressant was mentioned in their case record in the 6 months prior to dementia diagnosis. If the the antidepressant was continued after dementia diagnosis patients were also classified in this group. The second exposure group consisted of those prescribed an antidepressant in the 6 months after dementia diagnosis. Patients with AD who were not prescribed an antidepressant in the one-year window around dementia diagnosis served as control group.
Baseline covariates recorded were age, gender, ethnicity, marital status, a neighbourhood-level index of multiple deprivation 26 , and MMSE score closest to dementia diagnosis. To account for cerebrovascular co-morbidity we ascertained if an ICD-10 diagnosis of vascular (F01) or mixedtype Alzheimer's disease (F00.2) was mentioned in the follow-up period. General physical health and multi-morbidty was described through the 'Physical illness and disability problems' subscale of the Nation Outcome Scales (HoNOS65+) instrument. The HoNOS65+ is a standard measure of patient wellbeing used in UK mental health and dementia services and subscales are each rated 0 (no problem) to 4 (severe or very severe problem). 27, 28 In addition to the physical illness subscale, we also ascertained subscales relating to mental health symptoms and functional abilities. To facilitate interpretation, we dichotomised these to 'minor or no problem' (scores of 0 and 1) and 'mild to severe problems' (scores 2 to 4). Further, HoNOS65+ mental health problem scores were used to define subgroups of patients according to their neuropsychiatric symptom profile.
Statistical analysis
Analyses were conducted using STATA 13 software. Patients prescribed antidepressants were compared to the remainder with respect to other covariates. Patients were followed-up until their death or a census date on 10 th December 2016. We used log-rank tests to compare survival between exposure groups and then applied Cox regression models to investigate associations between antidepressant prescription and survival. In order to reduce impact of confounding by indication, propensity scores were calculated. 29 These represent the probability of being treated with an antidepressant based on a regression model which included all the above mentioned covariates and we included the propensity score in a Cox model.
Results
Population characteristics
Among the 10,011 patients diagnosed with AD initially identified, of which 8,695 had an MMSE score recorded at diagnosis. 5,473 patients fulfilled inclusion criteria. Of these, 2415 (44.1%) died in the follow-up period and mean (SD) follow-up time to death or the end of the observation period was 3.5 (2.4) years. 901 (16.5%) patients were prescribed an antidepressant prior to dementia diagnosis, of which 472 (8.6%) remained on the medication after diagnosis. 347 (6.3%) patients were prescribed an antidepressant after dementia diagnosis.
Characteristics of antidepressant non-receivers and the two exposure groups are compared in Table 1 . Antidepressant receivers were younger, more likely to be female, from a White ethnic background, and from more deprived areas. Those receiving antidepressants after dementia diagnosis had lower cognitive scores than those without or prior antidepressant prescription.
Further patients prescribed antidepressants had worse scores on HONOS65+ subscales for agitated behaviour, non-accidental self injury, hallucinations or delusions, depressed mood, physical illness, and functional scales (activities of daily living, occupation and activities, social relationships). No signifcant difference in cerebrovascular co-morbidty was detected between groups.
Predictors of mortality
Adjusted and unadjusted multivariate Cox regression models are presented in Table 2 . In models adjusted for demographics and cognition the following factors were assciated with higher mortality in the study cohort: higher age, being male, White ethnicity background, being from more deprived areas and having a lower MMSE. In addition, poorer physical health and functional status, as well as the following neuropsychiatric symptoms were associated whith increased mortality:agitated behaviour, hallucinations or delusions, and depressed mood. Of note, two factors associated with antidepressant prescribing (lower age and female gender) were linked to better survival.
Antidepressant receipt and survival
A log rank test demonstrated significant differences in survival function between antidepressant non-receivers and those prescribed antidepressants before or after dementia diagnosis (chi 2 =14.0, p<0.01). Cox regression models also showed significant associations between antidepressant prescription and an increased risk for all-cause mortality. Associations did not seem to differ significantly between those prescribed antidepressant prior and after dementia diagnosis and remained significant after including a broad range of confounders into the models (Table 3) . We created standard propensity scores from all available variables and included those as covariates in a Cox regression model. In propensity score adjusted models both exposure groups differed in 95% confidence intervals, but equal hazard ratios of 1.22 compared to non-rescription were detected.
Stratified analyses according to neuropsychiatric symptom profiles
We assessed the effect of antidepressant prescription in patients with depressed mood (n=483), with depressed mood and other co-morbid neuropsychiatric symptoms (agitated behaviour and/or psychotic symptoms; n=170), with agitation and/or psychosis, but no depressive symptoms (n=653), and in patients without any of the aforementioned neuropsychiatric problems (n=3,975) (see Table 4 ). In patients with depressed mood antidepressant prescription prior to, but not after dementia diagnosis, was significantly associated with an increased mortality risk. In patients with agitated behaviour and/or psychotic symptoms antidepressant prescription did not lead to a significantly increased risk of death. Only in the group suffering from depressed mood and comorbid agitation/psychosis a trend towards increased mortality was detected in those prescribed an antidepressant after dementia diagnosis in a fully adjusted Cox regression model (HR 1.91; 95% CI 0.89-4.11; p=0.08). Most notably, in the group without depression, agitation or psychosis, both antidepressant prescription prior and after dementia diagnosis resulted in an increased hazard for all-cause mortality.
Differences in survival times
In those who died in the follow-up period (n=2,415), mean (SD) survival time from dementia diagnosis to death was 3.3 (2.3) years. Mean (SD) survival time for patients not prescribed antidepressants was 3.4 (2.3) years, and for patients taking antidepressants prior to dementia diagnosis 3.1 (2.1) years and post dementia diagnosis 3.0 (2.3) years (p=0.01). This indicates a mean difference of 3-4 months of survival between antidepressant receivers and non-receivers.
Survival time was significantly (p<0.01) shorter for patients with depressive symptoms (2.9 (SD
2.3) years) than those presenting without depressed mood (3.4 (SD 2.3) years). In those who
suffered from depressed mode and died in the follow-up period (n=266), no significant differences in survival time were detected between antidepressant receivers and non-receivers (p=0.77).
Discussion
In this study of 5,473 patients with clinically diagnosed AD, we found that people who took antidepressant medications in the year encompassing the dementia diagnosis were more likely to die during the follow up period. This association was similar in those with pre-dementia antidepressant prescritption and those receiving the medication after dementia diagnosis and remained robust after adjustment for potential confounders and in analyses including a propensity score representing the risk of being treated. Moreover, the presence of neuropsychiatric, functional, and physical health problems and socio-economic deprivation were associated with a higher mortality risk in this cohort of AD patients.
Approximately 23% of the sample with AD were prescibed at least one antidepressant medication, and almost three quarters of those already before dementia diagnosis. Compared to those not taking antidepressants, participants taking such medication had a higher presence of neuropsychiatric symptoms, had worse functioning according to HONOS65+ scores and worse physical health. Altogether, these findings suggest that participants taking antidepressant medications had a higher presence of risk factors for mortality, which may partly explain our findings. However, the association of interest remained robust, although relatively small, after adjustment for these confounders.
There are a number of potential mechanisms by which antidepressant medication may influence mortality in people with AD. First, antidepressant medications are associated with a higher risk of several medical conditions also associated with higher mortality risk; these include falls 19, 30, 31 , poor bone health 32 , fractures 33 , and potentially cardiovascular disease 34 . Second, antidpressants may interact with other medications taken by people affected by AD and increase the likelihood of adverse effects. For example, the use of some antidepressants could lead to a prolongation of QT intervals, especially if co-prescribed with other medications commonly used in people affected by AD, such as antipsychotics. 35 Finally, some antidepressants (like tricyclic medications) may have a role on on basal heart rate and heart rate variability 36 , two important factors for mortality. 37 Previous literature considering the relationship between antidepressant use and mortality among people with AD is equivocal and our findings add to a growing picture of a complex relationship.
A large study including 20,050 participants affected by various types of dementia 20 reported that the use of antidepressant medications is associated with a significant lower risk of mortality.
However, other large studies have reported an association with increased mortality. 19 Several reasons could explain these conflicting findings in the literature and our own data. First, factors as cognitive function, diagnostic criteria for AD, and the presence of diseases at higher risk of mortality could explain the differences. Second, the authors of the first study found that only a prolonged use of antidepressants (more than 3 years) was associated with a lower risk of mortality, whilst using antidepressants at the time of diagnosis or less than 3 years was not associated with any decreased risk. 20 Finally, our study had a considerably longer follow-up time than Enache et al. 20 , who only observed their patients for two years after dementia diagnosis. It is conceivable that the hazardous effects of antidepressants only become apparent later in the dementia disease course.
The findings of our study should be interpreted within its limitations. First, it is an observational study and so we cannot exclude that some potential confounders not considered in our analysis could play a role in the association between antidepressants and mortality. Second, we did not have any information regarding the causes of mortality.Third, the type of antidepressant was not ascertained and so we are not able to conclude if a particular medication or class is responsible for the increased mortality found. Fourth, we assessed the use of antidepressants only in a window ranging from six months before to six months after first dementia diagnosis and this could introduce a bias in our results. Depressive symptoms, such as social withdrawal can be a prodromal feature of AD, 38 rather than representing clinical depression and we are unable to deliniate the clinical phenotype of our study sample. Fifth, we did not have sufficient information to adjust for level of education, although this is a factor partly reflected in the index of neighbourhood-level socio-economic status and a prospective studies have not found any association between educational level and survival in AD 39 . Sixth, co-morbidity was primarily ascertained through the HoNOS65+ 'Physical illness and disability problems' subscale, which although being widely used as routine measure of clinical outcome in dementia services in the UK, is a relatively brief measure.
Conclusion
Our findings suggest that antidepressants should be used cautiously in older people affected by AD, consistent with a longitudinal study showing that antidepressants are associated with a higher risk of adverse outcomes, including falls, hyponatraemia, cardiovascular and cerebrovascular conditions. 40 Since the benefits of antidepressant medications on mood in dementia may be limited, the prescribing clinician should carefully consider the risks and benefits of doing so. As this is a retrospective observational study, more solid evidence could be achieved through replicating these results in a prospective cohort study or a randomized controlled trial and future studies are needed to better elucidate the true role of antidepressants in AD. Table 3) ± using HoNOS65+ mental health problem subscales (a score of 2 or more represents a problem) * p<0.05 # p<0.10
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